Author

SIN GON KIM

Observed name: Sin Gon Kim

Institutions: Yonsei University, Korea University, CHA University Bundang Medical Center, CHA University, Yonsei University Health System

Observed institutions: Yonsei University, Korea University, CHA University Bundang Medical Center, CHA University, Yonsei University Health System

ORCID: 0000-0002-7430-3675

Observed ORCID: 0000-0002-7430-3675

OpenAlex ID: A5042353635

Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Rodica Pop-Busui, Søren Rasmussen, et al. · JAMA Internal Medicine · 18

Oral Semaglutide and Change in Cardiovascular Risk Factors in High-Risk Type 2 Diabetes: A Post Hoc Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Sharon L. Mulvagh, Silvio E. Inzucchi, et al. · JAMA Cardiology · 6

First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial

2026 · Nikolaus Marx, John E. Deanfield, et al. · JAMA Cardiology

Efficacy and safety of adding a fourth oral antidiabetic drug versus metformin dose escalation in patients with type 2 diabetes inadequately controlled on triple oral combination therapy ( EFFORT ): A 24‐week, randomized, open‐label, multicenter trial

2026 · So Ra Kim, Jun Hwa Hong, et al. · Diabetes Obesity and Metabolism

Author response for "Efficacy and Safety of Combining Empagliflozin in People with Type 2 Diabetes Mellitus Uncontrolled with Metformin and Sitagliptin: A Randomized, Double-Blind, Multicenter, Therapeutic Confirmatory, Phase 3 Clinical Trial"

2025 · Seung‐Hwan Lee, Kyung Ah Han, et al. · Publons reviews and discussion

1471-P: Impact of SGLT2 Inhibitors with ARB or ACE Inhibitors on Cardiorenal Outcomes in Type 2 Diabetes without Preexisting Cardiovascular or Renal Disease

2025 · YOUNG-EUN KIM, JUNG A. KIM, et al. · Diabetes

468-P: Use of New Glucose-Lowering Drugs and the Risk of Major Adverse Cardiovascular Events in People with Type 2 Diabetes and Prior Stroke

2023 · JAE HYUN BAE, JIMI CHOI, et al. · Diabetes

834-P: Efficacy and Tolerability of Initial Triple Combination Therapy with Metformin, Dapagliflozin, and Saxagliptin Compared with Conventional Stepwise Add-on Therapy in Drug-Naïve Patients with Type 2 Diabetes—A Randomized, 104-Week, Open-Label, Active-Controlled Trial

2023 · NAM HOON KIM, JI YOON KIM, et al. · Diabetes

1426-P: Socioeconomic Disparities in Mortality among Young Adults with Diabetes—A Nationwide Cohort Study in South Korea

2023 · JI YOON KIM, NAM HOON KIM, et al. · Diabetes

1384-P: Serum Fibroblast Growth Factor 1 Levels and Its Association with ß-Cell Function and Insulin Sensitivity in Adults with Glucose Intolerance

2022 · JI YOON KIM, JIMI CHOI, et al. · Diabetes

Works count: 10

Citation count: 24

H-index: 2

I10-index: 1